The impact of schistosomiasis treatment on the entry of a clade A, CCR5-tropic HIV pseudovirus16 into cytobrush-derived cervical CD4+ T cells, the pre-defined primary trial endpoint, was assessed in all participants (Fig. 2a and Supplementary Figs. 3–4). The gene discussed is CCR5; the disease is schistosomiasis.